| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
4 companies
Neil Exter last filed a Form 4 in September 2025, as Director at RVMD. The filings on record cover 4 companies. Neil Exter's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Neil Exter's trades have earned a middling insider score of 66/100 across 5 rated trades. Over a 12-month horizon, 80.0% of those trades were profitable, with an average 12-month return of +28.9%.
At the last filing, the largest reported position was 28,815 shares of RVMD.
Neil Exter has 21 Form 4 filings on record from June 2016 to September 2025, across 5 companies: Director at Maze Therapeutics (MAZE), 2025; Director at Revolution Medicines (RVMD), 2020–2022; Pliant Therapeutics (PLRX), 2020–2022, and 2 more.
The 27 reported transactions were 11 option or other derivative awards, 7 open-market sales, 4 other transactions and 3 conversions, plus smaller numbers of other types.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
Shares as reported in the last Form 4 for each company; the most recent is from September 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 8, 2022 | RVMD Revolution Medicines, Inc. | Director | Sell | 0 | $0.00 | - | New | +2.0% | +26.6% | |
| Jun 4, 2021 | RVMD Revolution Medicines, Inc. | Director | Sell | 0 | $0.00 | - | New | -2.2% | -37.3% | |
| May 26, 2021 | RVMD Revolution Medicines, Inc. | Director | Sell | 0 | $0.00 | - | New | -16.2% | -48.7% | |
| Mar 27, 2017 | CTMX Cytomx Therapeutics, Inc. | Director | Sell | 0 | $0.00 | - | New | - | - |